Myristicin
Based on 1 Customer Validation
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.54%
- CAS. Nr.: 607-91-0
- Formel: C11H12O3
- Molecular Weight:192.21
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen
MoreAlle EGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
EGFR |
ERK |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KB | IC50 |
75 μg/mL
Compound: 27
|
Antitumor activity against human KB cells assessed as cell growth inhibition
Antitumor activity against human KB cells assessed as cell growth inhibition
|
[PMID: 36858050] |
| RAW264.7 | IC50 |
48.6 μM
Compound: 21
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by Griess reagent based assay
|
[PMID: 31642320] |
Myristicin (7.8-31.25 μM; 48 h) can delay the proliferation of gastric cancer cells and induce endoplasmic reticulum (ER) stress and apoptosis; at the same time, Myristicin reduces the expression of cell cycle proteins, increases the expression of Bax, and activates caspase enzyme, and enhances the release of cytochrome C and mitochondrial ROS levels [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human gastric cancer cells
-
Concentration:7.8125, 15.625, and 31.25 μM
-
Incubation Time:48 h
-
Result:Significantly decreased expression of cyclins, increased Bax expression.
Myristicin (200 mg/kg; po; single dose) treated 6 hours in advance, on acetic acid (AA)-induced small Mouse experimental colitis model has preventive and protective effect[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Experimental colitis model in mice[4]
-
Dosage:200 mg/kg
-
Administration:po; single dose, 6 h before Rectal AA (colitis inducer) instillation
-
Result:Reduced cellular oxidative stress induced by AA, and relieved the histopathological colonic damage, alleviated inflammation in the AA-induced colitis.
Chemical Information
-
CAS. Nr. 607-91-0
-
Appearance Liquid (Density: 1.1437 g/cm3)
-
Molecular Weight 192.21
-
Formel C11H12O3
-
Color Colorless to light yellow
-
SMILES
C=CCC1=CC(OC)=C2OCOC2=C1
-
Synonyms
Myristicine
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (520.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Kalbhen DA, et al. Nutmeg as a narcotic. A contribution to the chemistry and pharmacology of nutmeg (Myristica fragrans).Angew Chem Int Ed Engl. 1971 Jun;10(6):370-4. [Content Brief]
[2]. Dawidowicz AL, et al. Simple and rapid determination of myristicin in human serum.Forensic Toxicol. 2013 Jan;31(1):119-123. Epub 2012 Aug 15. [Content Brief]
[4]. Song J, et al. Myristicin Suppresses Gastric Cancer Growth via Targeting the EGFR/ ERK Signaling Pathway. Curr Mol Pharmacol. 2023;16(7):712-724. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.2026 mL | 26.0132 mL | 52.0264 mL | 130.0661 mL |
| 5 mM | 1.0405 mL | 5.2026 mL | 10.4053 mL | 26.0132 mL | |
| 10 mM | 0.5203 mL | 2.6013 mL | 5.2026 mL | 13.0066 mL | |
| 15 mM | 0.3468 mL | 1.7342 mL | 3.4684 mL | 8.6711 mL | |
| 20 mM | 0.2601 mL | 1.3007 mL | 2.6013 mL | 6.5033 mL | |
| 25 mM | 0.2081 mL | 1.0405 mL | 2.0811 mL | 5.2026 mL | |
| 30 mM | 0.1734 mL | 0.8671 mL | 1.7342 mL | 4.3355 mL | |
| 40 mM | 0.1301 mL | 0.6503 mL | 1.3007 mL | 3.2517 mL | |
| 50 mM | 0.1041 mL | 0.5203 mL | 1.0405 mL | 2.6013 mL | |
| 60 mM | 0.0867 mL | 0.4336 mL | 0.8671 mL | 2.1678 mL | |
| 80 mM | 0.0650 mL | 0.3252 mL | 0.6503 mL | 1.6258 mL | |
| 100 mM | 0.0520 mL | 0.2601 mL | 0.5203 mL | 1.3007 mL |
Myristicin Related Classifications
HY-N2510 Related Classifications
Powered by Bioz